The initial findings were subsequently verified by a controlled double-blinded human trial in which monotherapy by LithoLexal® decreased the serum levels of TNF-α in individuals with moderate to severe osteoarthritis [53]. The gene discussed is TNF; the disease is osteoarthritis.